Medex Screen Ltd.
The Company
Medex Screen Ltd. develops, manufactures and markets breakthrough screening technologies for the healthcare professional.
The company was founded in 1999 by a group of experienced physicians and scientists. Their goal was to provide an effective, rapid and safe screening solution that accurately predicts early stage and asymptomatic pathologies of internal organs and systems, as well as diagnosing the acute and chronics ones.
MedexTest is accurate, safe, affordable, cost effective, easy to use, non-invasive and radiation free. It is a highly effective method of predicting the probability of disorders of the internal organs. It screens the cardiovascular, gastroenterological, hepatic, immune, respiratory, endocrine, genitourinary and spinal cord systems.
Extensive clinical trials have proven that Medex Test is far more effective than traditional examination methods. It provides healthcare professionals with an additional examination tool that is a fast and economical diagnostic aid.
Medex Test is the first of several advanced screening devices which Medex Screen Ltd is developing.
The Problem
Experts agree that an advanced and efficient screening technology with high predictive sensitivity follows an easier and much less complicated treatment administration, which consequently, it will reduce the hospital and outpatient costs.
Medex Test, Medex Screen’s flagship product, is a unique computer-based tool based on neuroreflexological and pathophysiological principles. It was designed for ambulatory care, private and public internal-medicine clinics, ER services, hospitals and occupational insurance companies, and for general screening of risk groups.
Technology (product) Description
Medex Test is an advanced technology for any stage screening and monitoring of functional and pathological disorders of internal organs. Medex Test effectively integrates principles of neuroreflexology and pathophysiology in a non-invasive, radiation-free device that is simple to operate and provides fast, accurate results.
Medex Test screens the cardiovascular, gastroenterological, hepatic, immune, respiratory, endocrine, genitourinary and spinal cord systems.
The methodological principle behind Medex Test relies on detecting changes in the electrical impedance of certain dermal-visceral zones (DVZs) following the internal organs’ pathologies.
The development of Medex Test followed a rigorous path:
- Research into general methods of screening
- Analysis of the duration of impedance registration
- Development of a sensor to measure the DVZ
- Analysis of normative corridor parameters corresponding to individual patients’ conditions
- Identifying and mapping of measured zones
- Development of the algorithms and coefficients of determination of damage to internal organs
The product consists of an active sensor, a passive electrode, a hasp key and software.
Competition
“Medex Test" main advantages are:
- Non-invasive, radiation free and Painless.
- Short testing time - about 20 minutes.
- High sensitivity accuracy.
- No preparation is needed in order to take the test.
- The testing does not require any active cooperation from the patient
- The test is able to distinguish between pathological and functional impairment.
- Determines the level of severity of the disease.
- Monitoring of treatment efficiencies.
- Short training period needed for practitioners.
- A portable system.
The Team
Board of Directors
Meir Engleret, Ph.D. - Chairman
Moshe Golan, Managing Director
Avraham Goldiner
Dr. Alexander Kanevsky, CTO
Yochanan Korman
Gurion Meltzer
Ilan Shavit, Lawyer
Advisory Board Members
Prof. Eshel Ben-Jacob, Full Professor at the Faculty of Exact Science, Tel Aviv University
Prof. Zamir Halpern, Head of Gastroenterology Institute, Sorousky Medical Center, Tel Aviv
Prof. Pier Luigi Meroni, IRCCS Istituto Auxologico Italiano, University of Milan, Milan, Italy
Prof. Yehuda Shoenfeld, FRCP. Head of Internal Medicine “B”, The Center of Autoimmune Diseases, Tel Hashomer, Israel
Prof. Zamir Halpern, Head of Gastroenterology Institute, Sorousky Medical Center, Tel Aviv
Prof. Pier Luigi Meroni, IRCCS Istituto Auxologico Italiano, University of Milan, Milan, Italy
Prof. Yehuda Shoenfeld, FRCP. Head of Internal Medicine “B”, The Center of Autoimmune Diseases, Tel Hashomer, Israel
Company Status
Medex Screen Ltd incorporated on March 1, 1999.
Medex Screen has invested so far in the development more than 2 Million USD.
Medex Screen will continue to invest in its R&D activities to obtain its ultimate goal.
Medex Screen will continue to cooperate and work with most professionals and qualified people in each field.
Medex Screen has invested so far in the development more than 2 Million USD.
Medex Screen will continue to invest in its R&D activities to obtain its ultimate goal.
Medex Screen will continue to cooperate and work with most professionals and qualified people in each field.
Contact
Medex Screen Ltd
8 Haplada st.
Arad 89092
Israel
Tel: +972-8-9953584
Fax: + 972-8-9972026
EMAIL : info@medexscreen.com
Back to top
